Analysts expect that Sanofi (NYSE:SNY) will post $10.38 billion in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Sanofi’s earnings, with the highest sales estimate coming in at $10.70 billion and the lowest estimate coming in at $9.88 billion. Sanofi reported sales of $9.56 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 8.6%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, February 14th.

On average, analysts expect that Sanofi will report full-year sales of $10.38 billion for the current financial year, with estimates ranging from $40.38 billion to $42.22 billion. For the next fiscal year, analysts expect that the company will post sales of $42.53 billion per share, with estimates ranging from $41.59 billion to $43.38 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Sanofi.

A number of equities research analysts have recently commented on the stock. BidaskClub raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Morgan Stanley cut shares of Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday. Barclays raised shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Finally, raised shares of Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. Sanofi presently has a consensus rating of “Hold” and a consensus target price of $53.50.

Large investors have recently made changes to their positions in the company. Fisher Asset Management LLC lifted its position in shares of Sanofi by 3.3% during the 3rd quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock valued at $701,156,000 after buying an additional 443,799 shares in the last quarter. Founders Financial Securities LLC purchased a new position in shares of Sanofi during the 2nd quarter valued at approximately $907,000. AMG National Trust Bank lifted its position in shares of Sanofi by 5.3% during the 2nd quarter. AMG National Trust Bank now owns 51,423 shares of the company’s stock valued at $2,464,000 after buying an additional 2,594 shares in the last quarter. Alethea Capital Management LLC purchased a new position in shares of Sanofi during the 3rd quarter valued at approximately $794,000. Finally, Assetmark Inc. lifted its position in shares of Sanofi by 34.4% during the 3rd quarter. Assetmark Inc. now owns 158,305 shares of the company’s stock valued at $7,882,000 after buying an additional 40,484 shares in the last quarter. Hedge funds and other institutional investors own 9.13% of the company’s stock.

Shares of Sanofi (SNY) opened at $44.62 on Friday. The company has a market cap of $115,081.63, a P/E ratio of 14.40, a PEG ratio of 2.52 and a beta of 0.86. Sanofi has a one year low of $38.45 and a one year high of $50.65. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/03/10-38-billion-in-sales-expected-for-sanofi-sny-this-quarter.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Get a free copy of the Zacks research report on Sanofi (SNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.